Skip to main content

Advertisement

Table 4 Targeted treatment in luminal-B breast cancer

From: Luminal-B breast cancer and novel therapeutic targets

Pathway Agent Supplier Class Phase Study design Eligible population
IGF BMS-754807 BristolMyersSquibb IGF-1R/IR TKI II BMS-754807 ± letrozole ER-positive locally advanced/metastatic breast cancer, progressed on prior nonsteroidal aromatase inhibitors
  Cixutumumab ImClone IGF-1R mAb I/II Cixutumumab and temsirolimus Locally advanced/metastatic breast cancer progressed on one or two chemotherapy lines
  MK-0646 Merck IGF-1R mAb I/II MK-0646 and fulvestrant and dasatinib Locally advanced/metastatic ER-positive breast cancer with no previous treatment in metastatic setting
  Dalotuzumab Merck IGF-1R mAb II Dalotuzumab and ridaforolimus versus standard care ER-positive locally advanced/metastatic breast cancer, progressed on at least one line of endocrine therapy
  OSI-906 OSI IGF-1R/IR TKI II OSI-906 and endocrine therapy ± erlotinib ER-positive metastatic breast cancer, treated with ≤4 chemotherapy regimens
  CP-758171 Pfizer IGF-1R TKI I CP-758171 for two cycles prior to curative surgery Operable early breast cancer
FGF TKI-258 Novartis FGFR/VEGFR TKI II TKI-259 single agent HER2-negative, FGFR1 amplified and FGFR1 normal metastatic breast cancer
  AZD-4547 Astra Zeneca FGFR TKI II Exemestane ± AZD-4547 ER-positive locally advanced/metastatic breast cancer with high levels of FGFR1 expression
PI3K/AKT MK-2206 Merck AKT inhibitor II MK-2206 single agent Metastatic breast cancer with PIK3CA mutation and/or PTEN loss, progressed on at least one line of therapy
  MK-2206 Merck AKT inhibitor II MK-2206 and endocrine therapy ER-positive metastatic breast cancer progressed on endocrine therapy
  XL-147 Exelixis PI3K inhibitor II XL-147 and letrozole ER-positive metastatic breast cancer refractory to nonsteroidal aromatase inhibitors
  XL-765 Exelixis PI3K/mTOR inhibitor II XL-765 and letrozole ER-positive metastatic breast cancer refractory to nonsteroidal aromatase inhibitors
  1. ER, estrogen receptor; FGF, fibroblast growth factor; FGFR, fibroblast growth factor receptor; IGF, insulin-like growth factor; IGF-1R, insulin-like growth factor 1 receptor; mAb, monoclonal antibody; mTOR, mammalian target of rapamycin; PI3K, phosphoinositide 3-kinase; TKI, tyrosine kinase inhibitor; VEGFR, vascular endothelial growth factor.